Azitra Past Earnings Performance
Past criteria checks 0/6
Azitra's earnings have been declining at an average annual rate of -4.7%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 21.3% per year.
Key information
-4.7%
Earnings growth rate
43.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 21.3% |
| Return on equity | -112.0% |
| Net Margin | -9,259.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Azitra makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -9 | 6 | 5 |
| 30 Jun 24 | 0 | -10 | 6 | 5 |
| 31 Mar 24 | 1 | -12 | 5 | 4 |
| 31 Dec 23 | 1 | -13 | 4 | 4 |
| 30 Sep 23 | 1 | -15 | 4 | 4 |
| 30 Jun 23 | 0 | -16 | 4 | 5 |
| 31 Mar 23 | 0 | -14 | 4 | 5 |
| 31 Dec 22 | 0 | -13 | 4 | 6 |
| 30 Sep 22 | 0 | -13 | 4 | 6 |
| 31 Dec 21 | 0 | -12 | 4 | 5 |
| 31 Dec 20 | 0 | -7 | 3 | 4 |
Quality Earnings: AZTR is currently unprofitable.
Growing Profit Margin: AZTR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AZTR is unprofitable, and losses have increased over the past 5 years at a rate of 4.7% per year.
Accelerating Growth: Unable to compare AZTR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AZTR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: AZTR has a negative Return on Equity (-112.04%), as it is currently unprofitable.